

Dr Christelle RATIGNIER-CARBONNEIL
+33 (0) 7 77 49 95 92
christelle.ratignier-carbonneil@ansm.sante.fr
Nationality : french

Director General

**French National Agency for
Medicines and
Health Products Safety
(ANSM)**



- MANAGEMENT :** 20 years of managerial experience (teams, departments) in the public service, proven experience in change management, management of strategic projects
- PUBLIC HEALTH AND HEALTH SAFETY :** 21 years of health experience, confirmed mastery of French and European health organization, management of health policies, management of health crises
- COMMUNICATION :** 20 years of professional experience, media spokesperson, national and international speaker at seminars, congresses and assemblies
- DEONTOLOGY :** No conflict of interest – Declaration of Public Interests accessible on www.ansm.sante.fr

WORK EXPERIENCE

- From 06/22 : **Vice-Chair Management Board
European Medicines Agency (EMA)**
(Netherlands - Amsterdam)
- From 12/20 : **Director General
French National Agency for Medicines and Health Products Safety (ANSM)**
(France - Saint-Denis)
- 12/16 – 12/20 : **Deputy Director General for operations
French National Agency for Medicines and Health Products Safety (ANSM)**
(France - Saint-Denis)
- 05/12 – 11/16 : **Deputy Director – Head of the Health Products Department
National Health Insurance Fund (CNAM)**
(France - Paris)
- 11/10 – 05/12 : **Health Products Advisor of the Minister of Labor, Employment and Health
Ministry of Labor, Employment and Health**
(France - Paris)
- 06/07 – 11/10 : **Head of Clinical Evaluation Unit PTC-5
French National Agency for Medicines and Health Products Safety
(ANSM- ex AFSSAPS)**
(France - Saint-Denis)
- 10/03-05/07 : **Clinical manager of the Immunology Team
French National Agency for Medicines and Health Products Safety
(ANSM- ex AFSSAPS)**
- 01/02-09/03 : **Preclinical Assessor
French National Agency for Medicines and Health Products Safety
(ANSM- ex AFSSAPS)**

EDUCATION AND TRAINING

- 97-02 : **PhD in Immunology and Hematology : Effects of intravenous human immunoglobulins (IVIg) on the physiology of endothelial cells in a xenogenic situation**
University D. Diderot – France - Paris VII
- 96-97 : **D.E.A “ Biology and pharmacology of haemostasis and vessels”**
University D. Diderot – France - Paris VII

PUBLICATIONS

Regulatory activities and Public health

1. The French blood products supply database (MDSRAppro): an effective tool for long-term national surveillance of coagulation factors and management of supply shortages.
A coordination between Pharmacists, Physicians, Patients Association, Health Authorities and Pharmaceutical Companies.
Julie Azard, Peggy Chocarne, Marie-Christine Gensbittel, Valérie Chamouard, Chantal Rothschild, Norbert Ferré, Ségolène Clayessens, Bernadette Worms, Jérôme Vernois, Edmond-Luc Henry, Marion Elber, Claude Vigneron, Philippe Arnaud, Florence Suzan, Christelle Ratignier.
Journal of Thrombosis and Haemostasis July 2009; Volume 7, Supplement 2 ISTH Congress Boston
2. Management of Immune Tolerance Induction in France: a collaboration between Health Authorities and Haemophilia Care Centers.
Christelle Ratignier, Chantal Rothschild, Roseline d’Oiron, Valérie Chamouard, Nathalie Dumarcet, Edith Peyrezabes, Claude Négrier.
Haemophilia June 2008 Volume 14 Issue s2 WFH Congress Istanbul
3. The French blood products supply database (MDSRAppro): an effective tool for long-term national surveillance of coagulation factors. A coordination between Pharmacists, Physicians, Patients Association, Health Authorities and Pharmaceutical Companies.
Edith Peyrezabes, Marie-Christine Gensbittel, Valérie Chamouard, Chantal Rothschild, Norbert Ferré, Claude Guérois, Bernadette Worms, Jérôme Vernois, Edmond-Luc Henry, Marie Auzanneau, Claude Vigneron, Philippe Arnaud, Odile Kremp, Ségolène Clayessens, Christelle Ratignier.
Haemophilia June 2008 Volume 14 Issue s2 WFH Congress Istanbul
4. Factor VIII products and inhibitor development: concepts for revision of European regulatory guidelines.
Neugebauer B, Draï C, Haase M, Hilger A, Keller-Stanislawski B, Laitinen-Parkkonen P, Mentzer D, Rasmussen C, Ratignier C, Seitz R.
Haemophilia. 2008 Jan;14(1):142-4. Epub 2007 Dec 7. No abstract available.
5. Report of EMEA expert meeting on the revision of the Core spc and Note for guidance for human normal immunoglobulin for intravenous administration (IVIg)
EMEA/CHMP/BPWP/361857/2006 - London, 24 January 2008
6. Report of expert meeting on Factor VIII products and inhibitor development
EMEA/CHMP/BPWP/123835/2006 - London, 22 February 2007
7. Development of inhibitors and management in hemophiliac patients treated with FVIII or IX of plasma origin – Good practice recommendations – May 2006, Afssaps
8. Long-term national surveillance of coagulation factors supply in France. A coordination between pharmacists, physicians, patients association, health authorities and pharmaceutical companies. Christelle Ratignier, Valérie Chamouard, Claude Guérois, Chantal Rothschild, Frank Huet, Edith Fressinaud, Hervé Chambost, et al.
Haemophilia May 2006 Volume 12 Issue s2 WFH Congress Vancouver
9. French cohort of patients with hemorrhagic diseases by hereditary deficits in coagulation proteins – FranceCoarg Network Report – Descriptive data 2005 – INVS – May 2006

10. Assessment of the health risks associated with the exposure of the French population to aluminum - water, food, health products.

Sophie Gallotti, Juliette Hospitalier, Dominique Tricard (Afssa) - Anne Castot, Dominique Masset, Christelle Ratignier (Afssaps) - Nadine Frery and Claire Gourier-Frery (Invs) - Sébastien La Vieille, Marie-Hélène Loulergue (Afssa)

Inter-agency report - November 2003

11. Aluminum and toxicity - Bulletin des vigilances -

Christelle Ratignier

December 2003 Bulletin n° 18 – Afssaps

12. Who guidelines on non-clinical evaluation of vaccines

November 2003

Biomedical Research

13. Ratignier C., Poulot V., Rodallec A., Glotz D., 2001.

Differential activation of porcine endothelial cells by human xenoreactive antibodies.

Xenotransplantation. Vol 8. Supplement 1 : 88 (431)

14. Ratignier C., Rodallec A., Poulot V., Glotz D., 2001.

Human immunoglobulins for intravenous use can modulate xenogeneic endothelial cell activation

Xenotransplantation. Vol 8, Supplement 1 : 118 (606).

15. Ratignier C., Rodallec A., Poulot V., Glotz D., 2001.

Human immunoglobulins for intravenous use can modulate endothelial cell activation in xenogeneic conditions.

Scandinavian Journal of Immunology. Vol 54, Supplement 1 : 48 (634).

16. Ratignier-Courtat C., Rodallec A., Cholley B., Glotz D., 2000.

Modulation of endothelial cell activation by polyclonal immunoglobulins for intravenous use (IVIg).

JASN, Sept 2000, 11 : 670A.

17. Ball B., Mousson C., Ratignier-Courtat C., Guignier, F., Glotz D., Rifle G., 2000.

Antibodies to vascular endothelial cells in chronic rejection of renal allografts.

Transplantation Proceedings. 32: 353-354

18. Christelle Ratignier, Audrey Rodallec, Denis Glotz. Décembre 2000.

Modulation of endothelial cell activity by Human immunoglobulins for intravenous use (IVIg).

Oral communication at the Congress of the French Society of Immunology, Paris, Décembre 2000.

19. Schussler O., Genevaz D., Ratignier-Courtat C., Latremouille C., Goussev N., Glotz D., 1998.

IVIg and xenotransplantation.

Cardiovascular Engineering. 3 :112-119.

20. Ratignier-Courtat C., Genevaz D., Jouy N., Glotz D., 1997.

Human immunoglobulins for intravenous use (IVIg) inhibit complement-mediated lysis of endothelial cells by xenophile antibodies.

Fourth International Congress of Xenotransplantation, 1997. Nantes.